Research programme: bispecific antibodies - Gilead Sciences

Drug Profile

Research programme: bispecific antibodies - Gilead Sciences

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Developer Genmab; Gilead Sciences
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research HIV infections

Most Recent Events

  • 10 Aug 2016 Early research in HIV infections in USA (Parenteral) after August 2016
  • 10 Aug 2016 Gilead in-licenses DuoBody® technology from Genmab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top